Arcadia Investment Management Corp MI reduced its stake in Zoetis Inc (NYSE:ZTS) by 1.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,620 shares of the company’s stock after selling 205 shares during the period. Arcadia Investment Management Corp MI’s holdings in Zoetis were worth $2,071,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after buying an additional 346,167 shares in the last quarter. Polen Capital Management LLC lifted its holdings in Zoetis by 0.9% during the 2nd quarter. Polen Capital Management LLC now owns 10,188,554 shares of the company’s stock worth $1,156,299,000 after buying an additional 86,364 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in Zoetis by 40,874.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after buying an additional 7,061,550 shares in the last quarter. Northern Trust Corp lifted its holdings in Zoetis by 1.0% during the 2nd quarter. Northern Trust Corp now owns 5,963,894 shares of the company’s stock worth $676,842,000 after buying an additional 58,435 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Zoetis by 9.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after buying an additional 383,799 shares in the last quarter. Institutional investors own 90.05% of the company’s stock.
In related news, insider Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $123.51, for a total value of $756,251.73. Following the completion of the sale, the insider now directly owns 44,255 shares in the company, valued at approximately $5,465,935.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the sale, the executive vice president now owns 33,190 shares of the company’s stock, valued at $4,181,608.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,332 shares of company stock valued at $4,258,182. Company insiders own 0.29% of the company’s stock.
A number of research firms have recently weighed in on ZTS. Craig Hallum increased their price target on Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and increased their price target for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. ValuEngine downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. SunTrust Banks increased their price target on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday, August 13th. Finally, Argus set a $140.00 price target on Zoetis and gave the company a “buy” rating in a research note on Wednesday, September 4th. Eight analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $123.69.
ZTS stock opened at $122.81 on Wednesday. The stock has a 50-day moving average price of $125.68 and a two-hundred day moving average price of $114.52. The stock has a market cap of $61.18 billion, a PE ratio of 39.24, a price-to-earnings-growth ratio of 3.18 and a beta of 0.87. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74. Zoetis Inc has a 1 year low of $78.90 and a 1 year high of $130.20.
Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 EPS. On average, analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. The ex-dividend date of this dividend is Monday, October 21st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.53%. Zoetis’s dividend payout ratio is 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What is Forex?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.